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RESUMO
Factibilidade, Segurança e Eficácia do  
Fechamento Percutâneo da Comunicação  
Interatrial em Crianças Pequenas
Introdução: A experiência com o fechamento percutâneo 
da comunicação interatrial (CIA) em crianças pequenas é 
limitada. Avaliamos a factibilidade, a segurança e a eficácia 
desse procedimento em crianças com peso < 20 kg. Métodos: 
Estudo descritivo observacional de uma coorte de crianças 
< 20 kg submetidas a tratamento percutâneo. Pacientes com 
dilatação ventricular direita e sintomas evidentes foram in­
cluídos. Implantamos próteses aprovadas pela ANVISA, sob 
monitorização ecocardiográfica transesofágica. Os pacientes 
foram avaliados 1 mês, 3 meses, 6 meses e 12 meses após. 
Resultados: Entre outubro de 1997 e maio de 2012, 80 pacien­
tes foram tratados. As medianas de idade e peso foram de 4 
anos (1­12) e 13,5 kg (5­20), respectivamente, 20 pacientes 
apresentavam alguma síndrome genética (25%) e 4 pacien­
tes (5%) apresentavam CIA adicional. Somente um paciente 
necessitou duas próteses. Dois pacientes tinham defeitos 
ABSTRACT
Background: The experience with percutaneous closure of 
atrial septal defect (ASD) in infants is limited. We sought to 
determine the feasibility, safety and efficacy of this procedure 
in children weighing < 20 kg. Methods: Observational study of 
a cohort of children weighing < 20 kg undergoing percutane­
ous closure. Patients with right ventricular enlargement and 
evident symptoms were included. ANVISA approved devices 
were implanted under transesophageal echocardiography moni­
toring. Patients were evaluated 1, 3, 6 and 12 months after 
the procedure. Results: Eighty patients were treated between 
October 1997 and May 2012. Median age and weight were 
4 years (1­12) and 13.5 kg (5­20), respectively, 20 patients 
had a genetic syndrome (25%) and 4 patients (5%) had an 
additional ASD. Only one patient required 2 devices. Two 
patients had associated defects that were treated in the same 
procedure (pulmonary valve stenosis and arteriovenous fistula). 
One patient developed total atrioventricular block during 
device implantation, solved spontaneously 36 hours after de­
vice removal, with no need for pacemaker implantation. This 
patient was successfully treated percutaneously 6 months later 
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without complications. Seventy­nine patients were discharged 
within 24 hours after the procedure. A mild residual shunt 
(1­2 mm) was observed in 5% of the cases before discharge. 
There was no residual shunt 6 months after the procedure. 
There were no complications in the late follow­up. Conclu-
sions: Percutaneous ASD closure in selected symptomatic 
infants is a feasible, safe and effective alternative and should 
be the first option therapy.
 
 
 
 
 
 
 
DESCRIPTORS: Heart septal defects, atrial. Prostheses and 
implants. Child.
T he first description of interatrial septal defects dates back to 1875 and was performed by Rokitansky, but their physiopathology and clinical picture started 
to be revealed only after 1941.1 Ostium secundum 
atrial septal defect (ASD) has the fourth or fifth highest 
incidence of congenital heart diseases, corresponding 
to approximately 5% to 10% of cases.2­4
With the gradual decrease in pulmonary vascular 
resistance, and improved hypertrophy and right ven­
tricular compliance within the first year of life, ASD 
begins to have hemodynamic consequences with right 
chamber volume overload. However, most of these 
patients remain asymptomatic during the first years of 
life. The defect is usually electively corrected before 
the child reaches school age, at around 5 years old. 
Occasionally, patients younger than 5 years with ASD 
develop isolated symptoms generated by pulmonary 
hyperflow, including recurrent respiratory infections, 
bronchospasm, congestive heart failure, or failure to 
thrive.5,6 This scenario is aggravated when the ASD is 
associated with prematurity, chronic pulmonary diseases 
(asthma, bronchodysplasia), genetic syndromes, or other 
systemic diseases (renal and liver failure, among others). 
These patients require early treatment. 
The surgical approach was considered the method 
of choice for ASD management for over four decades. 
Although it has very good results,7,8 it requires cardio­
pulmonary bypass, hemotherapy, and longer hospital 
stay, in addition to some postoperative morbidity, such 
as pain, infections, pericardial effusion, arrhythmias, and 
sternotomy scars.9­11 The first percutaneous ASD closure 
was described in 1976.12 With the technical advances 
and surgeons’ greater experience, percutaneous treatment 
has become the modality of choice for the management 
of most patients with ASD.13­19 Surgery is reserved for 
cases with unfavorable anatomy for the percutaneous 
approach, associated cardiac anomalies, or other types 
associados, os quais foram tratados no mesmo procedimento 
(estenose pulmonar valvar e fístula arteriovenosa). Um pa­
ciente desenvolveu bloqueio atrioventricular total durante 
o implante da prótese, resolvido espontaneamente 36 horas 
após a remoção da prótese, sem necessidade de implante 
de marca­passo. Esse paciente foi tratado percutaneamente 6 
meses após com sucesso, sem complicações. Setenta e nove 
pacientes receberam alta hospitalar em até 24 horas após o 
procedimento. Fluxo residual discreto (1­2 mm) foi observado 
em 5% dos casos antes da alta. Após 6 meses de seguimento, 
não foi detectado fluxo residual. Não houve complicações 
tardias no seguimento. Conclusões: O fechamento percutâneo 
da CIA em crianças pequenas selecionadas e sintomáticas é 
uma alternativa terapêutica factível, segura e eficaz, devendo 
ser a primeira opção para seu tratamento.
DESCRITORES: Comunicação interatrial. Próteses e implantes. 
Criança.
of ASD (e.g. ostium primum ASD, sinus venosus, and 
coronary sinus).19 Although the percutaneous treatment 
is well established for older children, adolescents, and 
adults, there are few reports on the use of this method 
in small children.20­24
This article describes an experience with the per­
cutaneous treatment of ASD in children weighing < 20 
kg, assessing its feasibility, efficacy, and safety.
METHODS
Study design
Observational, longitudinal descriptive study of 
a cohort of children weighing < 20 kg submitted to 
percutaneous closure of ostium secundum ASD in two 
cardiology referral centers in Brazil. Data collection 
was performed retrospectively, through medical record 
analysis. Demographic, clinical, echocardiographic, and 
hemodynamic data were collected. Parents or guard­
ians of patients were informed of the procedure and 
signed an informed consent approved by the ethics and 
research committee of both institutions.
Inclusion criteria
Children weighing < 20 kg with clinical and echo­
cardiographic diagnosis of ostium secundum ASD with 
hemodynamic consequences, characterized by right 
ventricular volume overload associated with one or 
more of the following diagnoses:
– congestive heart failure;
– recurrent respiratory infections (six or more epi­
sodes in 12 months);
– chronic pulmonary disease (e.g. pulmonary 
bronchodysplasia, asthma, etc.).
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– failure to thrive;
– genetic syndromes (e.g. Down syndrome, etc.);
– severe systemic disease (e.g. renal or liver failu­
re, etc.).
Exclusion criteria
Exclusion criteria included weight < 5 kg, ASD 
classified as non­ostium secundum, fixed pulmonary 
artery hypertension, presence of associated intracardiac 
defects with surgical indication, and unfavorable anatomy 
for percutaneous closure of the defect.19­25 The absolute 
diameter of the ASD was not considered an exclusion 
factor for the procedure, nor was a deficient anterior­
superior border, provided that the contralateral border 
was adequate.25 Patients with large ASDs that required 
devices that were too large for the size of the heart, 
with risk of interference with atrioventricular valve func­
tion and pulmonary venous or coronary sinus drainage 
were excluded. Patients with more than one deficient 
border (usually contralateral) around the defect, usu­
ally accompanied by thin and distensible atrial septum, 
were also excluded. Patients with two adjacent ASDs 
that could be occluded with only one prosthesis, with 
two large and distant ASDs, but with the possibility of 
occlusion with two devices; with two distant ASDs, but 
in which the smallest defect was < 3­4 mm (therefore, 
with no clinical significance); with cribriform ASD with 
multiple small defects that could be occluded with only 
one prosthesis; and with simple additional heart defects 
that could be treated by catheterisation, such as patent 
ductus arteriosus (PDA), pulmonary valve stenosis, or 
vascular malformation were not excluded. 
Prostheses used in the trial
The prostheses used in this trial were approved 
by the Brazilian Health Surveillance Agency (Agência 
Nacional de Vigilância Sanitária – ANVISA), with well­
established safety and efficacy in previous experiments 
in Brazil, the United States, and Europe.17,18,26­28 These 
were: Amplatzer® Atrial Septal Occluder and Amplatzer® 
Cribriform Occluder (St. Jude Medical Inc. – St. Paul, 
United States), Gore Helex® Atrial Septal Occluder (W.L. 
Gore & Associate – Newark, United States), Lifetech 
Cera® ASD Occluder (Lifetech Scientific Corporation – 
Shenzhen, China), Occlutech Figulla® (Occlutech AB 
– Helsingborg, Sweden), Cardia® Atriassept (CardioLogic 
Ltd.), and Nit­Occlud ASD­R® (PFM Medical Ag – Koln, 
Germany) (Figure 1).
The spatial conformation of these prostheses 
consists of two discs of varying sizes with a central 
connecting waist.17,18,27,28 With the exception of the 
Helex® prosthesis, all others use nitinol – an alloy of 
nickel and titanium – as the main component of their 
self­expanding mesh. Occlusion is performed by the 
filling of the septal orifice by the self­centring waist, 
which exerts radial force on the ASD edges, as well 
as physical barrier to blood flow exerted by the discs 
positioned in each of the atria after implantation.
Nitinol is also present in the Helex® prosthesis, but 
in the form of a helical strut that provides support to 
a dense mesh of polytetrafluoroethylene (PTFE), which 
has occluding power after it is fully exposed and po­
sitioned.26 In this prosthesis, the waist only connects 
the two disks and is not self­centring.
Procedure
The procedure was performed under general anaes­
thesia, controlled by fluoroscopy and transesophageal 
echocardiography (TEE) using a two­dimensional pae­
diatric probe suitable for children weighing < 20 kg 
with a Philips (Healthcare, DA – Best, the Netherlands) 
or General Electric (GE – United States) equipment. 
Femoral venous access was used in all patients, except 
in two, in whom the trans­hepatic route was necessary 
due to the absence of the hepatic portion of the inferior 
vena cava, caused by left atrial isomerism. Heparin 
at a dose of 100 IU/kg was administered through the 
lateral route of the venous sheath, immediately after 
its insertion. The right cardiac chambers were catheter­
ized and measures of pulmonary pressure were directly 
acquired. Calculations of pulmonary/systemic flow and 
resistance made using Fick’s method were restricted to 
cases with severe pulmonary hypertension.29
ASD measures assessed at baseline were evalu­
ated, as well as the appearance of its borders, through 
TEE25 (Figure 2). The total atrial septum length in the 
anterior­posterior and superior­inferior views was deter­
mined using the four­chamber projection and the short 
axis at the level of the aortic valve, respectively. This 
measurement was performed to assess the adequacy 
of prosthesis size selected for the size of the patient’s 
heart. The stretched ASD diameter measurement using 
Figure 1 – Prostheses used: A) Cardia® Atriassept (CardioLogic Ltd.) 
B) Figulla® ASD (Occlutech International AB), C) Helex® ASD (Gore 
Medical Inc.), D) Amplatzer® ASO (St. Jude Medical, Inc.), E) Nit 
Occlud® ASD – R (PFM Medical Ag.), and F) Cera® (Lifetech Scientific).
A B
D
E
F
C
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a low­pressure NuMed balloon (Hopkinton, United 
States) or AGA balloon (Golden Valley, United States), 
with the stopped­flow technique30 was performed when 
there were thin, flexible, or aneurysmal borders or 
in the presence of additional ASD in addition to the 
main defect (Figure 3). Balloon measurement was also 
performed in all cases in which the Helex® prosthesis 
was chosen; the selected prosthesis was two­fold larger 
than the measured value. Self­centring prostheses from 
0 mm to 2 mm larger than the central waist diameter 
Figure 2 – Two­dimensional echocardiographic assessment of atrial septal defect, showing its favorable aspect for percutaneous treatment. In the 
lower panel, to the right, analysis of flow through the defect (left atrium­right atrium) at the color flow mapping.
Figure 3 – Evaluation of the stretched diameter of ASD (using the stop­flow technique) by two­dimensional echocardiography (left) and fluoroscopy (right).
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of the balloon were chosen. In patients with single 
ASD with firm borders, the prosthesis of choice for 
implantation had a waist diameter that was 20% to 
30% greater than the largest diameter of the defect at 
baseline. The self­centring prostheses with central waist 
(Amplatzer® ASO, Figulla® ASD, Nit Occlud® ASD and 
Cera®) were used in most cases (Figure 4). The Helex®, 
Figulla® PFO, or Amplatzer® Cribriform prostheses, 
not self­centring, were selected in the presence multi­
fenestrated atrial septum, and were implanted through 
the most central orifice. The Helex® prosthesis was also 
occasionally employed for defects < 10­12 mm, both 
single and central. When there were two ASDs, self­
centring prostheses were used, implanted in the larger 
defect (usually anterior­superior), with closure of the 
additional ASD (usually posterior­inferior) resulting from 
the coverage of the disks around the central waist. Two 
prostheses were necessary in only one case, one self­
centring and the other cribriform, in order to occlude 
a more anterior ASD and a cribriform posterior­inferior 
septum (Figure 5).
In some patients, especially those whose weight was 
< 15 kg and who had smaller dimensions of the left 
atrium (LA), in order to prevent extrinsic LA compres­
sion, the opening of the left disc was performed after 
the TEE probe was pulled. To avoid possible prolapse 
of left disc through the anterior portion (retroaortic) 
of the atrial septum, some technical manoeuvres 
were employed, including clockwise rotation of the 
sheath (which is almost in parallel with the column 
in anterior­posterior projection at the fluoroscopy) and 
opening of the left disk in the left or right superior 
pulmonary vein. 
Prophylactic antibiotic therapy with second­generation 
cephalosporin was administered during prosthesis im­
plantation and maintained for 24 hours. Acetylsalicylic 
acid was introduced five days before the procedure at 
a dose of 3 mg/kg/day to 5 mg/kg/day and maintained 
for six months. Patients were hospitalized for at least 
24 hours for clinical observation, and were discharged 
from the hospital after undergoing a transthoracic echo­
cardiography (TTE) and electrocardiography (ECG), and 
after ruling out acute complications of the treatment. 
The presence of residual shunt was determined through 
the analysis of the Doppler color flow through the atrial 
septum. Any immediate low­speed residual shunt through 
the prosthesis mesh was disregarded. Residual shunt 
was considered as adjacent to the prosthesis border 
and classified as minimum (< 1 mm in diameter), small 
(1­2 mm), medium (2­4 mm), and large (> 4 mm).31
Follow-up 
Outpatient follow­up was performed at one month, 
three months, six months, and 12 months after the 
percutaneous treatment, accompanied by chest radio­
graphy, ECG, and TTE. After 12 months, follow­up was 
performed annually. Prophylaxis for infective endocar­
ditis was recommended for up to six months after the 
procedure in cases with total defect occlusion (Figure 
6), and indefinitely if any residual shunt was noticed 
through the atrial septum after six months. 
Definitions and studied variables for outcome 
assessment
The realisation of the procedure was defined as 
successful implantation with prosthesis release and ap­
propriate positioning in the atrial septum. Safety was 
assessed by complication rates.31 Higher incidence of 
death, brain embolism, cardiac perforation with tampon­
ade, endocarditis, need for reintervention (surgical or 
percutaneous), arrhythmias requiring permanent cardiac 
pacemaker or antiarrhythmic drugs for prolonged periods, 
pleural or pericardial effusion requiring surgical drain­
age, and need for surgery due to device embolisation 
were considered complications.
Figure 4 – Prosthesis implantation in the atrial septum. On the left, the prosthesis still attached to the delivery cable, which implies in tension to 
the system. On the right, the same prosthesis after being released, assuming a neutral position in relation to the interatrial septum.
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Figure 5 – Fluoroscopy demonstrating the simultaneous positioning of two Amplatzer® prostheses (ASO and Cribriform) in the interatrial septum. At 
the top, both prostheses positioned and still connected to the delivery system; at the bottom, after disconnecting the delivery cable.
Figure 6 – Transthoracic echocardiography showing good positioning of the two prostheses implanted in the interatrial septum, with no residual shunt 
six months after percutaneous treatment, as shown by the color flow mapping. RA, right atrium, LA, left atrium, RV, right ventricle; LV, left ventricle.
RA RA
LA
RV RV
LV LV
LA
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Minor complications included prosthesis embolisa­
tion with percutaneous removal, cardiac arrhythmias 
with no need for prolonged treatment, hematoma at 
the venous access site, retroperitoneal hematoma with 
no need for intervention, anaemia requiring blood 
products, non­cardiac infection, and several respiratory 
conditions (pulmonary edema, atelectasis, laryngitis). 
Efficacy was assessed by the total occlusion rates or by 
the presence of residual shunt with no hemodynamics 
consequences (with normal right ventricular dimensions) 
during follow­up.
Statistical Analysis
Statistical analysis was performed using the Sigmastat 
software, version 2011. The data are shown as absolute 
values and frequencies, means and standard deviations, 
or medians and ranges, according to sample distribution.
RESULTS
Between October of 1997 and May of 2012, 80 
patients (49 females) with a median age of 4 years (1­
12 years) and median weight of 13.6 kg (5­20 kg) were 
submitted to percutaneous ASD closure in two Brazil­
ian cardiology referral centers. Of these 80 patients, 
18 (22.5%) were younger than 2 years and 9 (11%) 
weighed < 10 kg. Twenty patients (25%) had genetic 
syndromes (Down syndrome, Holt­Oram syndrome, 
and other unknown syndromes) or multiple malforma­
tions (gastrointestinal, renal, neurological, bone). Ten 
(12.5%) had a history of prematurity. During routine 
catheterisation, none of the patients showed severe 
pulmonary artery hypertension, and all patients had 
mean pressure < 30 mmHg in the pulmonary artery. 
Seventy­six patients (95%) had a single ASD, with a 
mean diameter of 12 ± 4 mm at the TEE. Four patients 
had ASD with one or more additional orifices (5%). The 
balloon­stretched diameter assessment was performed in 
40 patients (50%), with a mean value of 16 ± 5 mm. 
The mean diameter of the chosen prosthesis was 16.9 ± 
5 mm and the mean profile of the long delivery sheath 
was 8 ± 1.5 F. The mean duration of procedures was 
80 ± 15 minutes. The distribution of prostheses used 
in the procedures is shown in Table 1.
Two patients had associated heart defects, treated 
percutaneously in the same procedure. One had mo­
derate pulmonary valve stenosis and was submitted to 
balloon pulmonary valvuloplasty prior to ASD occlusion. 
The other patient had pulmonary arteriovenous fistula 
presented in right lung base that resulted in significant 
cyanosis, which was successfully occluded with the 
Amplatzer® Duct Occluder II (Figure 7).
Technical success was achieved in all 80 patients 
(100%). However, a patient submitted to Helex® prosthe­
sis implantation had total atrioventricular block (TAVB) 
during prosthesis positioning, with no improvement after 
its full opening and locking into the final position in 
the atrial septum. The prosthesis was removed according 
to the usual technique. Since the patient had adequate 
junctional escape rhythm with no signs of low output, 
he was taken to the intensive care unit for monitoring, 
receiving intravenous corticosteroids, with no need for 
pacemaker stimulation during evolution.
The TAVB was solved in approximately 36 hours 
and the patient was discharged within 72 hours af­
ter confirmation of sustained sinus rhythm in Holter 
monitoring. This patient returned after – six months, 
was successfully submitted to ASD occlusion with 
Amplatzer® without complications. Only one patient 
with multiple distant ASDs required a second prosthesis, 
both successfully implanted. In the other patients with 
multiple ASDs, additional defects were occluded after 
device implantation in the main ASD. Except for one 
patient who had TAVB, and another with a congenital 
syndrome that awaited discharge to return to home 
care, all others were discharged within 24 hours after 
the procedure. There were no hemodynamic, vascular, 
or pulmonary complications. 
Slight/mild residual shunt (1­2 mm) was observed in 
four patients (5%) at the TTE prior to hospital discharge. 
The outpatient follow­up comprised 95% of the patients, 
lasting 4 ± 3 years. The rate of ASD occlusion in the 
first clinical evaluation at one month and six months 
after the procedure was 100%. The echocardiography 
showed no signs of interference with atrioventricular 
valve function or blood flow in the right superior pul­
monary vein or coronary sinus. There were no clinical 
complications detected during follow­up.
DISCUSSION
This prospective observational longitudinal study 
demonstrated that in children weighing < 20 kg with 
ASD with hemodynamic consequences and significant 
clinical impact, percutaneous closure is feasible, safe, 
and effective.
TABLE  
Distribution of prostheses used
Prosthesis Number %
Amplatzer® Septal Occluder 40 50
Lifetech Cera® ASD 13 16.25
Helex® ASD 10 12.5
Cardia Atriassept® 10 12.5
Occlutech Figulla® ASD 5 6.25
Nit Occlud® ASD­R 1 1.25
Amplatzer® Cribriform 
Occluder
1 1.25
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Clinical indications for early percutaneous 
closure
The decision to treat an ASD in children weigh­
ing < 20 kg was reserved for those patients in whom 
pulmonary blood flow resulting from the defect brought 
significant clinical consequences, characterized by 
congestive heart failure, recurrent respiratory conditions 
(six or more episodes in 12 months) and low weight 
gain. In addition, patients who benefit the most from 
early percutaneous approach are those with chronic 
pulmonary disease, several genetic syndromes, and 
severe systemic diseases.
In this clinical practice, when these conditions are 
not present, percutaneous treatment of ASD with hemo­
dynamic consequences (with enlarged right ventricle) 
is usually scheduled to occur when the child is aged 
between 4 and 5 years.
Procedure feasibility in young children
Until recently, there were some dogmas and 
uncertainties regarding the feasibility of performing 
percutaneous closure in small children. The catheter 
profile, the size of the devices, and the possibility of 
intracardiac trauma, among others, were reasons to 
justify the impossibility of percutaneous treatment. In 
this study, although such problems were not observed, 
considerable care was taken regarding the procedure. 
The femoral vein, although of a smaller calibre in young 
children, was not a limiting factor to the procedure in 
this series. The sheaths were advanced without tech­
nical difficulties and without vascular complications 
in all patients. The mean profile of 8F sheaths was 
suitable for the median weight of the sample (13 kg). 
The procedure was feasible even in a patient weigh­
ing 5 kg, with a genetic syndrome, in whom a long 
7F sheath was used to implant a 9­mm Amplatzer® 
prosthesis. Even in patients who do not have normal 
femoral venous access, the trans­hepatic route, used 
in two patients in this sample, allows the procedure 
to be performed. In these two cases, long 9F or 10F 
sheaths (the largest sheaths used in the present study) 
were employed uneventfully.
The smaller size of the left atrium can cause some 
difficulty to open the left disk of the commercially avail­
able prostheses, and thus should be performed more 
carefully and slowly. Pulling the TEE probe helped to 
prevent a possible extrinsic compression, which would 
further reduce the size of the left atrium. In patients with 
an appropriate window (common in young children), 
another possibility to properly guide the procedure 
would be the use of TTE.32 It was chosen not to use 
intracardiac echocardiography in this population due to 
the need for a second venous access. In this experience, 
the manoeuvres used to avoid disc prolapse on the left 
through the anterior portion (retroaortic) of the septum 
were effective. However, greater care when performing 
these manoeuvres was required due to the increased 
fragility of intracardiac structures. Despite the small 
number of patients with multiple ASDs in this study, 
the ASDs were occluded in all five patients with one 
or even two prostheses.
Percutaneous treatment of associated heart diseases 
using the same anaesthesia time of the ASD occlusion 
added no technical difficulty, nor did it influence the 
success of the procedure. The only additional care that 
was planned for the catheterisation was treating the 
associated disease first, thus preventing additional intra­
cardiac manipulations after the prosthesis implantation 
and release in the atrial septum, which could theoreti­
cally cause prosthesis displacement or embolisation. 
Thus, both the balloon pulmonary valvuloplasty and 
Figure 7 – To the left, coronary angiography demonstrating the presence of large pulmonary arteriovenous fistula originating from the middle lobar 
branch of the right pulmonary artery. In the center, control coronary angiography showing good prosthesis positioning, with fistula occlusion. To the 
right, chest fluoroscopy in the left oblique projection with cranial angulation showing the spatial association between the implanted prosthesis in 
the fistula and in the atrial septal defect (Amplatzer® ADO II and Amplatzer® ASD).
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the occlusion of the pulmonary atrioventricular fistula 
were performed before the ASD occlusion. 
Taking into consideration all the aforementioned 
aspects, technical success was achieved in 100% of 
cases. The only unsuccessful case was caused by an 
electrical complication requiring device removal. This 
high success rate reflects the group’s experience with 
the techniques and prostheses used and the manage­
ment of young children with severe congenital heart 
defects.
Although weight < 5 kg was considered an exclu­
sion criterion in this study, the percutaneous closure 
of ASD in preterm neonates weighing < 2­3 kg with 
bronchodysplasia and on mechanical ventilation has 
been performed in some centers, resulting in early 
extubation and optimal outcomes (Dr. John Cheatham, 
personal communication). This will probably be the 
next challenge in future experiments.
Safety in this population
In this series, percutaneous ASD closure in young 
children was shown to be very safe. The only severe 
complication was the development of TAVB in one 
patient. This TAVB probably resulted from the lack 
of the self­centring mechanism in the device used 
(Helex®) causing the device to fall into the coronary 
sinus, temporarily injuring the region of the atrioven­
tricular node, which required device removal and a 
subsequent new procedure. The implantation of a 
self­centring prosthesis a few months later minimized 
this lower migration and prevented the occurrence of 
TAVB. The small size of the atrial cavities, typical of a 
small child, may also have influenced the emergence 
of this complication during the attempted implanta­
tion. The transitory nature of TAVB and the successful 
implantation of a new prosthesis – the Amplatzer® – 
confirm the hypothesis that there was no permanent 
injury to atrioventricular node or electrical conduction 
bundles. In one study, percutaneous closure of ASD 
in young children resulted in rates of approximately 
4% of TAVB.33 However, large prostheses were used 
in that experiment.
This observation, together with those obtained from 
this and other trials, show the importance of proper 
patient selection for the percutaneous procedure, espe­
cially regarding the stringent selection of the size and 
type of device for the underlying anatomy.34
The use of balloons to assess the stretched ASD 
diameter did not involve complications resulting from 
the technique in this selected group of young children, 
demonstrating safety when well indicated. As for the 
cases in which it was decided not to use them (50%), 
there were no complications secondary to prosthesis 
under – or overestimation. The use of the balloon was 
restricted to the ASDs with features that complicated 
the choice of prosthesis (e.g. thin and redundant bor­
ders, etc.) or when the option was the use of prosthesis 
without self­centring mechanism (e.g., Helex®). Previ­
ously published works corroborate the non­mandatory 
use of this resource when choosing the prosthesis, with 
no impairment regarding the safety or the efficacy of 
the procedure in selected cases.30
One of the authors’ concerns was to avoid, as 
much as possible, the overestimation of the prosthesis 
chosen for implantation, which could interfere with the 
atrioventricular valve function or the blood flow in the 
left superior pulmonary vein or coronary sinus. None 
of the patients had such complications. The strategy of 
measuring the total length of the interatrial septum at 
the echocardiography (TEE and TTE) and avoiding pros­
thetic discs greater than those measures was probably 
effective in preventing these complications. Therefore, 
some authors recommend performing the angiography 
with the catheter placed in the left superior pulmonary 
vein in hepatoclavicular projection to obtain the inter­
atrial septum length measurement (Dr. Ziyad M. Hijazi, 
personal communication).
In this study, no vascular complications were 
observed due to the adequacy of the profile of the 
prostheses used (mean 8F) to the size of patients 
(median weight of 13 kg). In this sense, the use of 
the Amplatzer® in this population has been preferred, 
due to the lower profile of their implant sheaths 
when compared to similar prostheses, such as the 
Cera® or Figulla®. The launch of the Figulla Flex® 
II is expected, which will reduce the calibre of the 
sheath by 2F to 3F, allowing for a safer use of this 
device in this population.
Efficacy
The occlusion rate of 100% observed from one 
month to six months in all followed patients (95%) is 
consistent with previous experiences reported in the 
literature, and demonstrates the high efficacy of this 
procedure. The progressive endothelialisation of the pros­
theses explains the spontaneous occlusion of immediate 
residual shunt.35 Although this aspect was not assessed 
in this study, the concept of clinical efficacy must not 
be forgotten. Previous studies have demonstrated that 
young patients with ASD and who are highly symptom­
atic greatly benefit from the percutaneous procedure, 
with fast weight gain and significant improvement of 
recurrent pulmonary conditions.23
Study limitations
This study has obvious limitations, due to its des­
criptive design and lack of a control group. The lack 
of data for evaluation of clinical efficacy for this type 
of procedure (weight gain, improved symptoms) is also 
an important limitation. 
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CONCLUSIONS
Percutaneous closure of ASD in very symptomatic 
selected young children is a feasible, safe, and effective 
therapeutic alternative. As it is less invasive than surgery, 
especially considering that this subgroup of patients is 
at high­surgical risk, this therapeutic modality should 
be regarded as the option of choice in the management 
of these patients, and should be offered early.
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CLARIFICATIONS
After completion of data collection and drafting of 
this manuscript, the percutaneous closure of ASD was 
performed in seven more patients weighing < 20 kg 
between May of 2012 and May of 2013. Although 
similar results were obtained, a severe complication 
was observed in a patient undergoing occlusion by 
transhepatic route, due to the impossibility of peripheral 
venous access due to multiple previous hospitalisations. 
This patient with genetic syndrome, weighing 7 kg, with 
severe gastroesophageal reflux and chronic pulmonary 
disease, developed right hemothorax secondary to liver 
puncture. After drainage, there was satisfactory progress 
without additional complications. This complication, 
which was not related to the occlusion procedure itself, 
but rather to the process of obtaining an access route, 
indicates the frailty of some of these patients and does 
not invalidate the aforementioned observations.
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